Impact of cabozantinib on plasma adrenocorticotropic hormone and serum cortisol concentrations in individuals with metastatic renal cell carcinoma: a retrospective analysis - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Impact of cabozantinib on plasma adrenocorticotropic hormone and serum cortisol concentrations in individuals with metastatic renal cell carcinoma: a retrospective analysis

  • By

  • Yuji Hataya

  • Mayuka Kurata

  • Kimiaki Murabe

  • Takuro Hakata

  • Kanta Fujimoto

  • Toshio Iwakura

  • Toshinari Yamasaki

  • Naoki Matsuoka

  • November 4, 2025

Share

  • 1

    Cabozantinib (CABO) may induce primary adrenal insufficiency (PAI) in patients with metastatic renal cell carcinoma (mRCC).

  • 2

    A retrospective study analyzed plasma adrenocorticotropic hormone (ACTH) and serum cortisol levels in 18 patients treated with CABO.

  • 3

    Patients with elevated plasma ACTH levels during CABO treatment exhibited symptoms like fatigue and appetite loss.

  • 4

    The study found that regular monitoring of ACTH and cortisol levels is not currently recommended for TKI treatments.

  • 5

    The case study highlights the need for further research on TKI-induced adrenal dysfunction and its clinical implications.

Original Source(s)

Impact of cabozantinib on plasma adrenocorticotropic hormone and serum cortisol concentrations in individuals with metastatic renal cell carcinoma: a retrospective analysis

  • by Yuji Hataya, Mayuka Kurata, Kimiaki Murabe, Takuro Hakata, Kanta Fujimoto, Toshio Iwakura, Toshinari Yamasaki, Naoki Matsuoka

  • November 4, 2025

Related Content

The evolution of RTOG and NRG Oncology CNS tumors clinical trials

Comment on “Life’s essential 8 and specific cancer risk and mortality in men and women: a population-based cohort analysis of 332,417 United Kingdom participants” and the inclusion of sleep in cancer focused guidelines

Personalized Cancer Vaccine Linked to Three-Year Disease-Free Survival in Head and Neck Cancer

All 16 patients who received TG4050 after standard treatment remained disease-free, compared with 13 of 16 patients in the control group

  • September 16, 2026

  • 2 min